NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis → REPLAY AVAILABLE: $0.25 Cent Trades (From DTI) (Ad) Free EW Stock Alerts $87.21 +0.17 (+0.20%) (As of 11:15 AM ET) Add Compare Share Share Today's Range$86.03▼$87.3350-Day Range$84.23▼$95.5652-Week Range$60.57▼$96.12Volume375,863 shsAverage Volume3.51 million shsMarket Capitalization$52.55 billionP/E Ratio37.59Dividend YieldN/APrice Target$94.31 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Edwards Lifesciences alerts: Email Address Edwards Lifesciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside8.4% Upside$94.31 Price TargetShort InterestHealthy1.35% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.93Based on 18 Articles This WeekInsider TradingSelling Shares$16.03 M Sold Last QuarterProj. Earnings Growth12.27%From $2.77 to $3.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.76 out of 5 starsMedical Sector97th out of 931 stocksSurgical Appliances & Supplies Industry4th out of 17 stocks 2.3 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 13 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.35% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 16.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 3.8 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Edwards Lifesciences this week, compared to 11 articles on an average week.Search Interest8 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows58 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold 32,144.39% more of their company's stock than they have bought. Specifically, they have bought $49,729.00 in company stock and sold $16,034,814.00 in company stock.Percentage Held by InsidersOnly 1.27% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.27% in the coming year, from $2.77 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 37.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 37.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.80.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 3.22. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 7.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Edwards Lifesciences Stock (NYSE:EW)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesMay 22, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) CFO Sells $508,781.25 in StockMay 14, 2024 | insidertrades.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells $439,050.00 in StockMay 10, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $73,359.20 in StockMay 8, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) CEO Buys $49,729.20 in StockMay 3, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) Director Sells $2,487,999.50 in StockMay 2, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,212,624.00 in StockMay 1, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 7,250 SharesMay 29 at 1:52 AM | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 23, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Raised to "Buy" at CitigroupMay 22, 2024 | msn.comCitigroup Upgrades Edwards Lifesciences (EW)May 20, 2024 | finance.yahoo.comA fantastic week for Edwards Lifesciences Corporation's (NYSE:EW) 84% institutional owners, one-year returns continue to impressMay 20, 2024 | markets.businessinsider.comRobust Growth and R&D Focus Solidify Buy Rating for Edwards LifesciencesMay 16, 2024 | benzinga.comEdwards Lifesciences's Options: A Look at What the Big Money is ThinkingMay 15, 2024 | msn.comDeutsche Bank Upgrades Edwards Lifesciences (EW)May 14, 2024 | finance.yahoo.comIndian Rival Meril Accuses Edwards Lifesciences Of Anti-Competitive Behavior In EU Antitrust ComplaintMay 13, 2024 | msn.comIndia's Meril files EU antitrust complaint against Edwards: reportMay 13, 2024 | sg.finance.yahoo.comEdwards Lifesciences hit with Meril's EU antitrust complaintMay 11, 2024 | finance.yahoo.comInvestors in Edwards Lifesciences (NYSE:EW) have seen respectable returns of 50% over the past five yearsMay 9, 2024 | seekingalpha.comEdwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)May 8, 2024 | finance.yahoo.comEdwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance DurabilityMay 7, 2024 | markets.businessinsider.comAssessing Edwards Lifesciences: Insights From 11 Financial AnalystsApril 30, 2024 | finance.yahoo.comEdwards Lifesciences Corporation (NYSE:EW) Q1 2024 Earnings Call TranscriptApril 30, 2024 | markets.businessinsider.comHold Rating Justified for Edwards Lifesciences Amid TAVR Segment UncertaintiesApril 27, 2024 | finance.yahoo.comEdwards Lifesciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 27, 2024 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)See More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today5/29/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$94.31 High Stock Price Target$107.00 Low Stock Price Target$57.00 Potential Upside/Downside+8.4%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$2.32 Trailing P/E Ratio37.52 Forward P/E Ratio31.42 P/E Growth3.22Net Income$1.40 billion Net Margins23.01% Pretax Margin26.19% Return on Equity22.86% Return on Assets16.52% Debt Debt-to-Equity Ratio0.08 Current Ratio3.75 Quick Ratio2.67 Sales & Book Value Annual Sales$6.14 billion Price / Sales8.54 Cash Flow$2.73 per share Price / Cash Flow31.84 Book Value$11.08 per share Price / Book7.86Miscellaneous Outstanding Shares602,600,000Free Float594,947,000Market Cap$52.45 billion OptionableOptionable Beta1.10 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 56)CEO & Director Comp: $2.27MMr. Scott B. Ullem (Age 57)Corporate VP & CFO Comp: $1.35MMr. Donald E. Bobo Jr. (Age 62)Corporate Vice President of Strategy & Corporate Development Comp: $1.27MMr. Larry L. Wood (Age 58)Corporate VP and Group President of TAVR & Surgical Structural Heart Comp: $1.49MDr. Todd J. Brinton FACCM.D., Corporate VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVice President of Investor RelationsMr. Arnold A. Pinkston (Age 65)Corporate VP & General Counsel Mr. Dirksen J. LehmanCorporate Vice President of Public AffairsMs. Christine Z. McCauley (Age 59)Corporate Vice President of Human Resources Mr. Gary I. Sorsher (Age 59)Senior Vice President of Quality & Regulatory Compliance More ExecutivesKey CompetitorsAbbott LaboratoriesNYSE:ABTIntuitive SurgicalNASDAQ:ISRGStrykerNYSE:SYKBoston ScientificNYSE:BSXMedtronicNYSE:MDTView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 49,751 shares on 5/28/2024Ownership: 0.017%Cetera Investment AdvisersBought 98,338 shares on 5/24/2024Ownership: 0.024%Cetera Advisors LLCBought 24,242 shares on 5/24/2024Ownership: 0.006%PGGM InvestmentsBought 2,172 shares on 5/24/2024Ownership: 0.000%Scott B UllemSold 5,625 sharesTotal: $508,781.25 ($90.45/share)View All Insider TransactionsView All Institutional Transactions EW Stock Analysis - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EW shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price target for 2024? 19 Wall Street research analysts have issued 12 month target prices for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they expect the company's stock price to reach $94.31 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2024? Edwards Lifesciences' stock was trading at $76.25 at the beginning of 2024. Since then, EW stock has increased by 14.2% and is now trading at $87.04. View the best growth stocks for 2024 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 8,000,000 shares, a decline of 16.9% from the April 30th total of 9,630,000 shares. Based on an average daily volume of 3,260,000 shares, the short-interest ratio is currently 2.5 days. Approximately 1.4% of the shares of the company are sold short. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) announced its quarterly earnings data on Thursday, April, 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. The medical research company earned $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a trailing twelve-month return on equity of 22.86%. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Honeytree U.S. Equity ETF (BEEZ), Fundamentals First ETF (KNOW), Tema Cardiovascular and Metabolics ETF (HRTS), IQ Winslow Focused Large Cap Growth ETF (IWFG), Global X Aging Population ETF (AGNG), Guru Favorite Stocks ETF (GFGF) and Fidelity Disruptive Medicine ETF (FMED). When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences issued an update on its second quarter 2024 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of 0.670-0.710 for the period, compared to the consensus earnings per share estimate of 0.700. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.6 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.79%), Bank of New York Mellon Corp (3.15%), Price T Rowe Associates Inc. MD (1.08%), Janus Henderson Group PLC (0.88%), Champlain Investment Partners LLC (0.49%) and Capital International Investors (0.37%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More This page (NYSE:EW) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarNext President (Not Trump. Not Biden.)The Freeport SocietyWrite this ticker symbol down…StocksToTradeNvidia’s Quiet $1 Trillion PivotWeiss Ratings4 Cryptos BETTER than BitcoinTrue Market Insiders[Urgent!] Generational Wealth GameplanCrypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThe only AI company to buyPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.